59412-12-3

Basic information

• Product Name: DICHLOROQUINOLINE(2,5-)
• Synonyms: DICHLOROQUINOLINE(2,5-);2,5-DICHLOROQUINOLINE;Quinoline, 2,5-dichloro-
• CAS NO: 59412-12-3
• Molecular Formula: C₉H₅Cl₂N
• Molecular Weight: 198.05
• Mol File: 59412-12-3.mol
• Article Data: 6

Chemical Properties

• Melting Point: 76-77 °C(Solv: hexane (110-54-3))
• Boiling Point: 304.0±22.0 °C(Predicted)
• Appearance: /
• Density: 1.407±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.77±0.50(Predicted)
• CAS DataBase Reference: DICHLOROQUINOLINE(2,5-)(CAS DataBase Reference)
• NIST Chemistry Reference: DICHLOROQUINOLINE(2,5-)(59412-12-3)
• EPA Substance Registry System: DICHLOROQUINOLINE(2,5-)(59412-12-3)

Safety Data

• Hazardous Substances Data: 59412-12-3(Hazardous Substances Data)

Usage

General Description

Dichloroquinoline(2,5-) is a chemical compound with the molecular formula C9H5Cl2N. It is a derivative of quinoline, a heterocyclic organic compound. Dichloroquinoline(2,5-) is commonly used as an intermediate in the production of various pharmaceuticals and agrochemicals. It has also been studied for its potential as an anti-malarial drug due to its ability to inhibit the growth of the malaria parasite. In addition, dichloroquinoline(2,5-) has shown promising antimicrobial and antifungal properties, making it a versatile compound with potential applications in the field of medicine and agriculture.

Upstream product

• 90224-97-8 5-chloroquinoline 1-oxide 
• 635-27-8 5-chloroquinoline 
• 611-34-7 5-Aminoquinoline 
• 23981-22-8 5-chloro-2-quinolone 
• 445041-60-1 (E)-N-(3-chlorophenyl)-3-ethoxypropenamide 

Downstream Products

• 1423778-37-3 5-chloro-2-(phenylethynyl)quinoline 
• 1404491-66-2 5-chloro-2-(3,5-dimethylphenyl)quinoline 
• 1064137-50-3 2,5-dichloroquinoline-3-carbaldehyde 
• 1065479-84-6 N-((S)-1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine 
• 1065480-13-8 N-((R)-1-(5-chloro-2-(3-fluoro-phenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine 
• 1065480-15-0 N-(1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine 
• 1065482-48-5 2-(1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)isoindoline-1,3-dione 
• 1065482-47-4 1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethanol 
• 1065482-49-6 1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethanamine 
• 1065482-46-3 5-chloro-2-(3-fluorophenyl)quinoline-3-carbaldehyde 
• 59412-13-4 2,5-dichloro-3-phenyl-quinoline 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds of formula I' and formula II' and their pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity for the treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity.

Synthesis and biological evaluation of 2-(arylethynyl)quinoline derivatives as mGluR5 antagonists for the treatment of neuropathic pain

We described here the synthesis and biological evaluation of mGluR5 antagonists containing a quinoline ring structure. Using intracellular calcium mobilization assay (FDSS assay), we identified compound 5n, showing high inhibitory activity against mGluR5. In addition, it was found that compound 5n has excellent stability profile. Finally, this compound exhibited favorable analgesic effects in spinal nerve ligation model of neuropathic pain, which is comparable to gabapentin.

Synthesis of a fluorine-18-labelled derivative of 6-nitroquipazine, as a radioligand for the in vivo serotonin transporter imaging with PET.

Considerable efforts have been engaged in the design, synthesis and pharmacological characterization of radioligands for imaging the serotonin transporter, based on its implication in several neuropsychiatric diseases, such as depression, anxiety and schizophrenia. In the 5-halo-6-nitroquipazine series, the fluoro derivative has been designed for positron emission tomography (PET). The corresponding 5-iodo-, 5-bromo- and 5-chloro N-Boc-protected quipazines as labelling precursors, as well as 5-fluoro-6-nitroquipazine as a reference compound have been synthesized. 5-[(18)F]Fluoro-6-nitroquipazine has been radiolabelled with fluorine-18 (positron-emitting isotope, 109.8 min half-life) by nucleophilic aromatic substitution from the corresponding N-Boc protected 5-bromo- and 5-chloro-precursors using K[(18)F]F-K(222) complex in DMSO by conventional heating (145 degrees C, 2 min) or microwave activation (50 W, 30-45 s), followed by removal of the protective group with TFA. Typically, 15-25 mCi (5.5-9.2 GBq) of 5-[(18)F]fluoro-6-nitroquipazine (1-2 Ci/micromol or 37-72 GBq/micromol) could be obtained in 70-80 min starting from a 550-650 mCi (20.3-24.0 GBq) aliquot of a cyclotron [(18)F]F(-) production batch (2.7-3.8% non decay-corrected yield based on the starting [(18)F]fluoride). Ex vivo studies (biodistribution in rat), as well as PET imaging (in monkey) demonstrated that 5-[(18)F]fluoro-6-nitroquipazine ([(18)F]-1d) readily crossed the blood brain barrier and accumulated in the regions rich in 5-HT transporter (frontal- and posterial cortex, striata). However, the low accumulation of the tracer in the thalamus (rat and monkey) as well as the comparable displacement of the tracer observed with both citalopram, a -HT re-uptake inhibitor and maprotiline, a norepinephrine re-uptake inhibitor (rat), indicate that 5-[(18)F]fluoro-6-nitroquipazine ([(18)F]-1d) does not have the suggested potential for PET imaging of the serotin transporter (SERT).